2seventy bio, Inc. (TSVT)
(Delayed Data from NSDQ)
$4.75 USD
+0.19 (4.17%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.75 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.75 USD
+0.19 (4.17%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.75 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Zacks News
Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated
by Zacks Equity Research
Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.
2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 17.14% and 21.55%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in 2seventy bio (TSVT) Stock?
by Zacks Equity Research
Investors need to pay close attention to 2seventy bio (TSVT) stock based on the movements in the options market lately.
Will 2seventy bio, Inc. (TSVT) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
2seventy bio, Inc. (TSVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 26.22% and 5.93%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy, Sell or Hold Bristol Myers (BMY) Before Q2 Earnings?
by Ekta Bagri
Bristol Myers (BMY) has an uphill task at hand. Given the current challenges, we would advise investors to avoid BMY ahead of the second-quarter results.
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
by Zacks Equity Research
A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
by Zacks Equity Research
Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of -12.50% and 4.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to the first sales numbers of its newly approved gene therapy, Casgevy.
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
by Zacks Equity Research
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
by Zacks Equity Research
The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
by Zacks Equity Research
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma
by Zacks Equity Research
Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
by Zacks Equity Research
Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.
Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
by Zacks Equity Research
Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
Should You Buy 2seventy bio (TSVT) Ahead of Earnings?
by Zacks Equity Research
2seventy bio (TSVT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC
by Zacks Equity Research
Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
Biotech Stock Roundup: GSK's Q4 Results, VRTX Gains on Update, TSVT Up on REGN Deal
by Zacks Equity Research
Earnings from GSK and other updates from 2seventy bio (TSVT) were in focus in the biotech sector.
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
2seventy bio, Inc. (TSVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
by Zacks Equity Research
2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
All You Need to Know About 2seventy bio, Inc. (TSVT) Rating Upgrade to Strong Buy
by Zacks Equity Research
2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.